Answers are grounded in this paper and cite their sources.
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders affecting women of reproductive age, characterised by reproductive dysfunction alongside significant metabolic abnormalities. Among these, insulin resistance (IR) is a common and important pathophysiological feature in many women with PCOS and is associated with hyperandrogenism, ovulatory dysfunction, and long-term cardiometabolic complications, although its contribution varies across phenotypes. Accumulating evidence indicates that dysbiosis of gut microbiota contributes to glucose metabolic dysfunction in PCOS through microbial metabolites, immune signalling, and endocrine regulation. This narrative review synthesises current clinical and experimental evidence connecting gut microbiota dysbiosis to metabolic heterogeneity in PCOS, with a particular focus on insulin resistance, obesity, and geographical variability. We discuss the primary mechanisms by which gut microbiota regulates glucose metabolism, including altered short-chain fatty acid production, bile acid dysregulation, impaired incretin signalling, chronic low-grade inflammation, and bidirectional interactions between gut microbiota and sex hormones. These interconnected pathways converge on insulin signalling and collectively contribute to metabolic dysfunction in PCOS. Additionally, we summarise emerging therapeutic strategies targeting the gut microbiota–glucose metabolism axis, including probiotics, prebiotics, synbiotics, microbiota-targeted pharmacological agents, dietary interventions, and lifestyle modifications, and discuss their potential for phenotype-specific management of PCOS. Much of the causal evidence remains preclinical, and no validated microbial signature or microbiota-directed therapy is currently available for PCOS. Current evidence is constrained by substantial inter-study heterogeneity, inconsistent microbial signatures, the predominance of observational human studies, and the absence of standardised microbiota-based interventions and large-scale prospective clinical trials. Rather than viewing these mechanisms as isolated pathways, this review emphasises glucose metabolism as an important integrative process linking gut microbial dysbiosis to both metabolic and reproductive dysfunction in PCOS. This integrative perspective provides a conceptual framework for understanding the gut microbiota–glucose metabolism axis and may facilitate the development of mechanism-based, phenotype-specific microbiota-targeted therapeutic strategies for PCOS.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: